AcelRx Pharmaceuticals, Inc. (ACRX): Product News News

ACRX – FDA releases briefing docs for October 12 meeting of the Anesthetic and Analgesic Drug Products Advisory Committee.


Key Facts Surrounding This News Item


  • ACRX had a POWR Rating of F (Strong Sell) coming into today.
  • ACRX was -22.29% below its 10-Day Moving Average coming into today.
  • ACRX was -25.87% below its 20-Day Moving Average coming into today.
  • ACRX was -18.08% below its 50-Day Moving Average coming into today.
  • ACRX was -20.37% below its 100-Day Moving Average coming into today.
  • ACRX was -2.75% below its 200-Day Moving Average coming into today.
  • ACRX had returned +30.86% year-to-date leading up to today’s news, versus a +9.11% return from the benchmark S&P 500 during the same period.

More Info About AcelRx Pharmaceuticals, Inc. (ACRX)


AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of acute pain. The company was founded in 2005 and is based in Redwood City, California.
View our full ACRX ticker page with ratings, news, and more.

ACRX at a Glance

ACRX Current POWR Rating™
Overall POWR Rating™
ACRX Current Price $3.34 0.60%
More ACRX Ratings, Data, and News

ACRX Price Reaction

The day of this event (Oct. 10, 2018)
ACRX Closing Price$3.60 35.66%
ACRX Volume30,444,800
3,152.90% from avg
Leading up to this event
ACRX 1-mo return18.46%
After this event
ACRX 1-day return33.42%
ACRX 3-day return33.25%
ACRX 5-day return36.14%

ACRX Price Chart


The Top Stocks For 2019

More AcelRx Pharmaceuticals, Inc. (ACRX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ACRX News
Page generated in 0.6773 seconds.